Literature DB >> 6487691

Source and regulation of 17 alpha-hydroxyprogesterone during baboon pregnancy.

E D Albrecht, G J Pepe.   

Abstract

The present study determined the source and regulation of 17 alpha-hydroxyprogesterone (17-OHP4) during mid-late baboon pregnancy. Serum 17-OHP4 (ng/ml) in 5 untreated baboons increased from low values at mid-late gestation to a mean (+/- SEM) of 0.49 +/- 0.02 during the final 20 days of gestation. Fetectomy of 5 baboons resulted in serum 17-OHP4 concentrations which declined to and remained at baseline. Serum 17-OHP4 concentrations were 5- to 10-fold greater (P less than 0.001) in the uterine, utero-ovarian, and umbilical veins than peripherally. Apparently the fetal adrenal provides precursors for placental 17-OHP4 formation because the fetal adrenal gland develops delta 5-3 beta-hydroxysteroid dehydrogenase only late in gestation, and because the fetal adrenal and not the placenta has the capacity for 17-hydroxylation. Thus, at mid-late gestation the placenta appears to supply a major, and at term the corpus luteum a minor portion of the total 17-OHP4. Administration of the estrogen antagonist ethamoxytriphetol (MER-25, 15 mg/kg BW) to 4 baboons did not affect 17-OHP4 during mid-late gestation, when the placenta was the only source of 17-OHP4. However, MER-25 resulted in serum 17-OHP4 concentrations (ng/ml) at term which were greater (1.08 +/- 0.10, P less than 0.001) than in untreated baboons (0.49 +/- 0.02). Prior removal of the corpus luteum of pregnancy in 4 animals subsequently given MER-25 prevented this rise in 17-OHP4. This suggests that the marked elevation in 17-OHP4 observed near term after MER-25 administration was of luteal origin and that antiestrogen enhanced 17-OHP4 secretion by the corpus luteum.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487691     DOI: 10.1095/biolreprod31.3.471

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  1 in total

1.  Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.

Authors:  Mark A Klebanoff; Paul J Meis; Mitchell P Dombrowski; Yuan Zhao; Atef H Moawad; Allison Northen; Baha M Sibai; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Kenneth J Leveno; Menachem Miodovnik; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian M Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman
Journal:  Am J Obstet Gynecol       Date:  2008-05-23       Impact factor: 8.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.